75 related articles for article (PubMed ID: 24576622)
1. Differential outcome of MEK1/2 inhibitor-platinum combinations in platinum-sensitive and -resistant ovarian carcinoma cells.
Cossa G; Lanzi C; Cassinelli G; Carenini N; Arrighetti N; Gatti L; Corna E; Zunino F; Zaffaroni N; Perego P
Cancer Lett; 2014 Jun; 347(2):212-24. PubMed ID: 24576622
[TBL] [Abstract][Full Text] [Related]
2. Costunolide induces apoptosis in platinum-resistant human ovarian cancer cells by generating reactive oxygen species.
Yang YI; Kim JH; Lee KT; Choi JH
Gynecol Oncol; 2011 Dec; 123(3):588-96. PubMed ID: 21945308
[TBL] [Abstract][Full Text] [Related]
3. Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.
Yanagie H; Hisa T; Ogata A; Miyazaki A; Nonaka Y; Nishihira T; Osada I; Sairennji T; Sugiyama H; Furuya Y; Kidani Y; Takamoto S; Takahashi H; Eriguchi M
Biomed Pharmacother; 2009 Sep; 63(8):553-60. PubMed ID: 18571892
[TBL] [Abstract][Full Text] [Related]
4. FoxO-1 contributes to the efficacy of the combination of the XPO1 inhibitor selinexor and cisplatin in ovarian carcinoma preclinical models.
Corno C; Stucchi S; De Cesare M; Carenini N; Stamatakos S; Ciusani E; Minoli L; Scanziani E; Argueta C; Landesman Y; Zaffaroni N; Gatti L; Perego P
Biochem Pharmacol; 2018 Jan; 147():93-103. PubMed ID: 29155058
[TBL] [Abstract][Full Text] [Related]
5. Studies on combinations of platinum with paclitaxel and colchicine in ovarian cancer cell lines.
Yunos NM; Beale P; Yu JQ; Strain D; Huq F
Anticancer Res; 2010 Oct; 30(10):4025-37. PubMed ID: 21036717
[TBL] [Abstract][Full Text] [Related]
6. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin.
O'Neill CF; Koberle B; Masters JR; Kelland LR
Br J Cancer; 1999 Dec; 81(8):1294-303. PubMed ID: 10604725
[TBL] [Abstract][Full Text] [Related]
7. Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells.
Gatti L; Benedetti V; De Cesare M; Corna E; Cincinelli R; Zaffaroni N; Zunino F; Perego P
J Inorg Biochem; 2012 Aug; 113():94-101. PubMed ID: 22717676
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of a monofunctional platinum compound and its activity alone and in combination with phytochemicals in ovarian tumor models.
Arzuman L; Beale P; Yu JQ; Proschogo N; Huq F
Anticancer Res; 2014 Dec; 34(12):7077-90. PubMed ID: 25503135
[TBL] [Abstract][Full Text] [Related]
9. Combination of Genistein and Cisplatin with Two Designed Monofunctional Platinum Agents in Human Ovarian Tumour Models.
Arzuman L; Beale P; Proschogo N; Yu JQ; Huq F
Anticancer Res; 2015 Nov; 35(11):6027-39. PubMed ID: 26504026
[TBL] [Abstract][Full Text] [Related]
10. Combinations of platinums and selected phytochemicals as a means of overcoming resistance in ovarian cancer.
Huq F; Yu JQ; Beale P; Chan C; Arzuman L; Nessa MU; Mazumder ME
Anticancer Res; 2014 Jan; 34(1):541-5. PubMed ID: 24403514
[TBL] [Abstract][Full Text] [Related]
11. Antidepressants and platinum drugs.
Engelmann BJ; Ryan JJ; Farrell NP
Anticancer Res; 2014 Jan; 34(1):509-16. PubMed ID: 24403509
[TBL] [Abstract][Full Text] [Related]
12. Combinations of resveratrol, cisplatin and oxaliplatin applied to human ovarian cancer cells.
Nessa MU; Beale P; Chan C; Yu JQ; Huq F
Anticancer Res; 2012 Jan; 32(1):53-9. PubMed ID: 22213288
[TBL] [Abstract][Full Text] [Related]
13. Platinum drug effects on the expression of genes in the polyamine pathway: time-course and concentration-effect analysis based on Affymetrix gene expression profiling of A2780 ovarian carcinoma cells.
Varma R; Hector S; Greco WR; Clark K; Hawthorn L; Porter C; Pendyala L
Cancer Chemother Pharmacol; 2007 May; 59(6):711-23. PubMed ID: 17021820
[TBL] [Abstract][Full Text] [Related]
14. Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells.
Serova M; Calvo F; Lokiec F; Koeppel F; Poindessous V; Larsen AK; Laar ES; Waters SJ; Cvitkovic E; Raymond E
Cancer Chemother Pharmacol; 2006 Apr; 57(4):491-9. PubMed ID: 16075278
[TBL] [Abstract][Full Text] [Related]
15. The role of glutathione (GSH) in determining sensitivity to platinum drugs in vivo in platinum-sensitive and -resistant murine leukaemia and plasmacytoma and human ovarian carcinoma xenografts.
Goddard P; Valenti M; Kelland LR
Anticancer Res; 1994; 14(3A):1065-70. PubMed ID: 8074451
[TBL] [Abstract][Full Text] [Related]
16. BRCA1-IRIS overexpression promotes cisplatin resistance in ovarian cancer cells.
Chock KL; Allison JM; Shimizu Y; ElShamy WM
Cancer Res; 2010 Nov; 70(21):8782-91. PubMed ID: 20940403
[TBL] [Abstract][Full Text] [Related]
17. Platinum(IV) complex with adamantylamine overcomes intrinsic resistance to cisplatin in ovarian cancer cells.
Horváth V; Blanárová O; Svihálková-Sindlerová L; Soucek K; Hofmanová J; Sova P; Kroutil A; Fedorocko P; Kozubík A
Gynecol Oncol; 2006 Jul; 102(1):32-40. PubMed ID: 16364413
[TBL] [Abstract][Full Text] [Related]
18. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
[TBL] [Abstract][Full Text] [Related]
19. JNK- and Akt-mediated Puma expression in the apoptosis of cisplatin-resistant ovarian cancer cells.
Zhao Z; Wang J; Tang J; Liu X; Zhong Q; Wang F; Hu W; Yuan Z; Nie C; Wei Y
Biochem J; 2012 Jun; 444(2):291-301. PubMed ID: 22394200
[TBL] [Abstract][Full Text] [Related]
20. Anticancer and chemosensitizing effects of 2,3-DCPE in ovarian carcinoma cell lines: link with ERK activation and modulation of p21WAF1/CIP1, Bcl-2 and Bcl-xL expression.
Villedieu M; Briand M; Duval M; Héron JF; Gauduchon P; Poulain L
Gynecol Oncol; 2007 May; 105(2):373-84. PubMed ID: 17276501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
